|Bid price||2.12||Open price||2.17|
|Ask price||2.22||Prev close||2.17|
Register now for FREE live Oxford BioMedica share prices, Oxford BioMedica stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Oxford BioMedica Level 2 Data, indepth research tools and investor commentary for Oxford BioMedica (OXB) and other London Stock Exchange equities.
Register now for FREE Oxford BioMedica share price charts
|Sector||Pharmaceuticals & Biotechnology||ISIN||GB0006648157|
|Activites||Oxford BioMedica plc is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp.||Index||n/a|
|Latest Share Price (p)||2.17||Net Gearing (%)||18.89|
|Market Capitalisation (£m)||30.73||Gross Gearing (%)||34.79|
|Shares in issue (m)||1,416.15||Debt Ratio||5.64|
|P/E Ratio||-2.75||Debt-to-Equity Ratio||0.11|
|Total dividends per share (p)||0.00||Assets / Equity Ratio||1.53|
|Dividend Yield (%)||0.00||Price to book value||3.45|
|Dividend cover (x)||0.00||ROCE||-1.12|
|Earning per share (p)||-0.79||EPS Growth (%)||-3.95|
|52 week high / low||3.78 / 1.33||DPS Growth (%)||n/a|
|Dec.Date||Type||Director||Pos||No. of Shares|
FTSE indices remained firmly in positive territory after Bank of England (BoE) stayed its benchmark interest rate at 0.5%, with mining, financial and property stocks gaining. BoE held interest rates at their record low and kept the size of its quantitative easing (QE) programme flat at £375bn....
Oxford Biomedica increased its FY pretax loss to £12.8m, from a loss of £10.3m. Revenue was £5.4m, from £7.8m. Research and development costs and administrative expenses contributed to the losses. "The Company made solid progress throughout the pipeline, notwithstanding the challenge we faced...
Story provided by StockMarketWire.com
Register now for FREE Oxford BioMedica company news
OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles. So here is a new title This one has got the charts at the top again & has a link to the old one....
Very strong rumours of a further predator around. CAT,WYEYH,JOHNSON&JOHNSON,MERCK to name a few.............could be an exciting week ...!
Very strong rumours of a further predator.........CAT,JOHNSON&JOHNSON,WYETH,MERCK to name a few. Could be an interesting week..!
Register now for FREE Oxford BioMedica share price discussions